MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$38,905K
EPS
-$0.52
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
19,801
9,840
7,317*
8,461
General and administrative
6,945
6,444
4,372*
4,746
Total operating expenses
26,746
16,284
11,689
13,207
Loss from operations
-26,746
-16,284
-11,689*
-13,207
Grant income
22
22
22*
-
Interest income
1,672
1,322
1,097*
953
Interest expense
1,575
1,564
1,524*
161
Change in fair value of warrant liabilities
12,278
-7,643
1,989*
-1,146
Total other income (expense), net
-12,159
7,423
-2,394*
1,938
Net income (loss) and comprehensive income (loss)
-38,905
-8,861
-14,084
-11,269
Basic EPS
-0.52
-0.14
-0.268
-0.21
Diluted EPS
-0.52
-0.14
-0.268
-0.21
Basic Average Shares
74,131,229
62,361,897
52,491,656
54,894,347
Diluted Average Shares
74,131,229
62,361,897
52,491,656
54,894,347
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net income (loss)
and comprehensive...
-$38,905K
(-711.20%↓ Y/Y)
Loss from operations
-$26,746K
(-139.29%↓ Y/Y)
Total other income
(expense), net
-$12,159K
(-290.55%↓ Y/Y)
Interest income
$1,672K
(80.56%↑ Y/Y)
Grant income
$22K
Total operating
expenses
$26,746K
(139.29%↑ Y/Y)
Change in fair value of
warrant liabilities
$12,278K
(315.74%↑ Y/Y)
Interest expense
$1,575K
(567.37%↑ Y/Y)
Research and development
$19,801K
(183.24%↑ Y/Y)
General and
administrative
$6,945K
(65.91%↑ Y/Y)
Buy us a coffee
Candel Therapeutics, Inc. (CADL)
Candel Therapeutics, Inc. (CADL)